Cathal Friel, Executive Chairman of Open Orphan talks about their £8.1m contract with a Major Global Pharma Company

Cathal Friel, Executive Chairman of Open Orphan #ORPH talks about their £8.1m contract with a Major Global Pharma Company.

Open Orphan announces that hVIVO, a subsidiary of Open Orphan plc, has signed an £8.1m contract with a major global pharmaceutical company to test its inhaled human rhinovirus (hRV) antiviral product using the hVIVO Asthma Human Challenge Study Model, which uses a hRV challenge agent (common cold virus).

Open Orphan plc (London and Euronext: ORPH) is a rapidly growing pharmaceutical service/contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The company provides services to Big Pharma, biotech and government/public health organisations.